Related Experiment Videos
[Endothelin in patients with chronic kidney failure]
K Nĕmecek1, V Bártová, M Jáchymová
1II. interní klinika 1. LF UK a VFN, Praha.
Casopis Lekaru Ceskych
|August 23, 1995
Summary
Endothelin (ET) levels are not significantly altered by arteriovenous fistula creation or erythropoietin (EPO) therapy in chronic renal failure patients. However, hemodialyzed patients exhibit higher ET concentrations compared to controls.
Area of Science:
- Cardiovascular Pathophysiology
- Renal Medicine
- Endocrinology
Context:
- Chronic renal failure (CRF) patients face high cardiovascular morbidity and mortality.
- Hypertension, anemia, and arteriovenous (AV) shunts are key contributing factors.
- Endothelin (ET), a potent vasoconstrictor, may play a role in CRF-related cardiovascular changes.
Purpose:
- To investigate the impact of AV fistula creation on plasma ET concentrations.
- To assess the effect of erythropoietin (EPO) therapy on plasma ET levels in anemic CRF patients.
- To compare ET levels in hemodialyzed patients with healthy controls and pre-dialysis CRF patients.
Summary:
- AV fistula construction did not significantly alter plasma ET levels.
- Subcutaneous EPO therapy for anemia correction did not lead to increased plasma ET.
- Hemodialyzed patients showed significantly higher plasma ET concentrations than healthy controls and CRF patients before dialysis.
Impact:
- Findings suggest ET is not acutely affected by AV fistula or EPO treatment in CRF.
- Elevated ET in hemodialyzed patients may contribute to their cardiovascular risk.
- Further research into ET's role in CRF cardiovascular complications is warranted.